Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. van Leeuwen FE, et al. Among authors: somers r. J Clin Oncol. 1994 May;12(5):1063-73. doi: 10.1200/JCO.1994.12.5.1063. J Clin Oncol. 1994. PMID: 8164031
A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, et al. Somers R, et al. J Clin Oncol. 1994 Feb;12(2):279-87. doi: 10.1200/JCO.1994.12.2.279. J Clin Oncol. 1994. PMID: 7509381 Clinical Trial.
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. van Leeuwen FE, et al. Among authors: somers r. J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7. doi: 10.1093/jnci/87.20.1530. J Natl Cancer Inst. 1995. PMID: 7563187
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R. van Leeuwen FE, et al. Among authors: somers r. J Clin Oncol. 1994 Feb;12(2):312-25. doi: 10.1200/JCO.1994.12.2.312. J Clin Oncol. 1994. PMID: 8113838
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, Somers R, Bijnens L, Noordijk EM, Peeters CD. Teodorovic I, et al. Among authors: somers r. J Clin Oncol. 1995 Nov;13(11):2819-26. doi: 10.1200/JCO.1995.13.11.2819. J Clin Oncol. 1995. PMID: 7595744 Clinical Trial.
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M. Hagenbeek A, et al. Among authors: somers r. J Clin Oncol. 1998 Jan;16(1):41-7. doi: 10.1200/JCO.1998.16.1.41. J Clin Oncol. 1998. PMID: 9440721 Clinical Trial.
223 results